
Molecular Toxicology Lab
Expertise
We bring together molecular pharmacology, toxicology, oncology and systems-level omics to understand disease mechanisms and translate them into safer therapeutics, better biomarkers and targeted interventions — working across cellular and animal models with advanced analytical platforms.
What we study
Core Areas of Expertise
01
Nanotoxicology and Nano–Immune Cell Interactions
The safety and molecular consequences of engineered nanomaterials, particularly those used in biomedical applications, with an emphasis on immune cell interactions, subtoxic effects, and mechanisms that inform regulatory decisions and safer material design.
02
Cancer Mechanisms, Senescence and Therapy Resistance
Tumour recurrence, chemoresistance and senescent cancer cell biology, with the goal of identifying molecular vulnerabilities that improve therapeutic responses across multiple cancer types.
03
Omics-Driven Toxicology and Biomarker Discovery
Using metabolomics and proteomics to map pathway-level changes underlying drug action and toxicity, identifying early detection biomarkers across both in vitro and in vivo models.
04
Neuroinflammation, Neurodegeneration and Aging Biology
How inflammatory and stress-response pathways drive neuronal dysfunction and age-related decline, linking autophagy, mitochondrial quality control, oxidative stress and cellular senescence to disease phenotypes.
05
Metabolic Disease and Mitochondrial Dysfunction
The molecular drivers of diabetes and its complications, including age-dependent mitochondrial abnormalities, and strategies to restore mitochondrial function and enhance cellular resilience.
How we work
Technical Capabilities and Platforms
Cellular and molecular biology
Live-cell and lysate-based luciferase assays, real-time PCR, western blotting, molecular cloning, plasmid preparation
In vivo approaches
Transgenic animal models, animal surgery and in vivo bioluminescent imaging — experience within the team, supported by the College animal facility
Toxicology assays
Cytotoxicity profiling, oxidative stress assays, mitochondrial function assays, trace metal toxicity models
Immunotoxicology
Mechanistic studies in immune cells, including mast cell-focused nanomaterial interactions
Flow cytometry
Phenotyping and functional readouts
Omics technologies
LC–MS metabolomics, NMR metabolomics, proteomic profiling, integrative pathway analyses
Who does what
Faculty Expertise

Dr. Sultan Almudimeegh
Bridges neuroinflammation and neurodegeneration with interests in cancer, aging biology and nanoparticle toxicology. Current focus: autophagy–senescence links through LRRK2 and senolytics in cancer therapy.

Dr. Nasser B. Alsaleh
Investigates the safety of engineered nanomaterials used in biomedical applications and nanomedicine, with a mechanistic focus on nano–immune cell interactions and subtoxic disruption of cellular homeostasis.

Dr. Homood As Sobeai
Focuses on discovering novel therapeutics for cancer and understanding how senescent cancer cells contribute to tumour recurrence, alongside the genetic and epigenetic factors shaping cancer progression.

Dr. Mohammed Almutairi
Studies the molecular mechanisms underlying diabetes and neurodegenerative disorders, with a strong emphasis on mitochondrial dysfunction in aging and strategies to improve mitochondrial quality.

Dr. Mohammed Assiri
Applies metabolomics and proteomics to uncover mechanisms of drug action, toxicity and disease progression, integrating LC–MS, NMR and proteomic profiling to identify early biomarkers.

Dr. Ali A. Alshamrani
Targets cancer therapy resistance, dissecting the signalling pathways and survival strategies that let tumours withstand treatment, and identifying vulnerabilities that can re-sensitise cancers to therapy.
How We Collaborate
We welcome collaborations in:
- Mechanistic toxicology and safety evaluation, including engineered nanomaterials
- Cancer signalling, senescence and resistance biology
- Omics-based biomarker discovery for toxicity and disease
- Neurodegeneration, neuroinflammation and mitochondrial biology
- Translational projects connecting bench findings to clinical and regulatory needs
